Compare PESI & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PESI | NNNN |
|---|---|---|
| Founded | 1990 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 370.3M | 340.2M |
| IPO Year | 1996 | 2023 |
| Metric | PESI | NNNN |
|---|---|---|
| Price | $15.60 | $6.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 261.8K | 241.6K |
| Earning Date | 05-08-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $642,000.00 | N/A |
| Revenue This Year | $34.62 | N/A |
| Revenue Next Year | $77.02 | N/A |
| P/E Ratio | ★ N/A | $446.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.58 | $5.13 |
| 52 Week High | $21.32 | $51.33 |
| Indicator | PESI | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 34.69 | 41.30 |
| Support Level | $14.18 | $5.13 |
| Resistance Level | $16.25 | $12.10 |
| Average True Range (ATR) | 0.82 | 0.54 |
| MACD | -0.38 | 0.19 |
| Stochastic Oscillator | 13.32 | 63.19 |
Perma-Fix Environmental Services Inc is a nuclear services company and provider of nuclear and mixed waste management services. The company's nuclear waste services include treatment and management of radioactive and mixed waste (waste containing both hazardous and low-level radioactive waste). The company operates through two segments: i) The treatment segment: It offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and ii) the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).